bluuebunny/crossref_metadata_2025_split huggingface dataset:
Relación de los estilos de liderazgo, cohesión grupal, potencia de equipo y rendimiento en jugadores de fútbol no profesionales
Authors: Huéscar Hernández Elisa , López Mora Clara , Cervelló Gimeno Eduardo 
Published: December 2017

El objetivo del presente trabajo fue analizar las relaciones entre tipos de
liderazgo (tarea y social), cohesión, potencia de equipo y rendimiento
en 334 futbolistas federados de las categorías Alevín, Cadete, Juvenil y
Absoluta, con una edad media de 15.97 (DE = 3.31). Los cuestionarios
utilizados fueron de Liderazgo auténtico (ALQ), tarea (LSS), Cohesión
grupal (CG), Potencia de equipo (CPEA) y rendimiento, que mostraron
índices de ajuste óptimos (χ2/DF = 1.313 p = 0; CFI = 0.997; TLI =
0.994; RMSEA = 0.032; SRMS = 0.0343). Los resultados indican que
el estilo de liderazgo, especialmente liderazgo tarea (p = 0.37) influye
indirectamente en el rendimiento a través de la CG (p = 0.17) y CPE (p
= 0.21). Como conclusión, se propone la mejora del rendimiento grupal
a partir de la optimización de modelos de conducta individuales.
Symptoms of Anxiety and Depression Modulate the Recognition of Facial Emotion
Authors: Ferrer da Rosa Natália Mendes , Ferreira Borges Vinícius , Cheffer Leonardo , Torro Alves Nelson , Estanislau Célio 
Published: December 2017

Previous studies have shown that depression and anxiety are associated
to changes in the recognition of facial expression. In the present
research, a non-clinical sample was evaluated with respect to trait
and state anxiety and depression symptoms. In the experimental task,
participants evaluated facial expressions of happiness, anger, sadness, and
fear, presented at four intensities (25, 50, 75, and 100%), as well as the
neutral face. Results showed that the trait anxiety was associated with a
better recognition of anger, fear, and happiness. For depression, we only
found differences between groups for emotional attribution to neutral
faces, in which participants scoring high in depression were more likely
to attribute fear to neutral faces. Findings indicate an improvement of
the recognition of happiness, anger, and fear in trait anxiety, whereas
symptoms of depression and state anxiety were associated to changes in
the evaluation of neutral faces in non-clinical individuals.
Whole-Genome Sequence of the Novel
Enterobacter
Bacteriophage Arya with an Integrase Pseudogene, Isolated from the Gut of the Formosan Subterranean Termite
Authors: Tikhe Chinmay Vijay , Gissendanner Chris R. , Husseneder Claudia 
Published: January 2018

ABSTRACT

We isolated and sequenced the novel
Enterobacter
bacteriophage Arya from termite gut. The genome showed synteny to lytic bacteriophage genomes; however, the genome encodes a truncated, putatively nonfunctional integrase pseudogene. Lysogeny-related genes were previously observed in certain lytic phages, but their role and evolution remain unclear.
Complete Genome Sequences of Three Novel
Saimiri sciureus
Papillomavirus Types Isolated from the Cervicovaginal Region of Squirrel Monkeys
Authors: Chen Zigui , Wood Charles E. , Abee Christian R. , Burk Robert D. 
Published: January 2018

ABSTRACT

The complete genome sequences of three novel
Saimiri sciureus
papillomavirus (SscPV) types (SscPV1 to SscPV3) isolated from the cervicovaginal region of squirrel monkeys were characterized. These three PV types share 78.1 to 83.3% nucleotide sequence identities with each other across the complete L1 open reading frame and cluster in the genus
Dyoomikronpapillomavirus
.
Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
Authors: Alten Rieke , Mariette Xavier , Lorenz Hanns-Martin , Galeazzi Mauro , Cantagrel Alain , Nüßlein Hubert G , Chartier Melanie , Elbez Yedid , Rauch Christiane , Le Bars Manuela 
Published: December 2017

IntroductionAn understanding of real-world predictors of abatacept retention is limited. We analysed retention rates and predictors of abatacept retention in biologic-naïve and biologic-failure patients in a 12-month interim analysis of the 2-yearAbataCepTIn rOutiNe clinical practice (ACTION) study.MethodsACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. In this 12-month interim analysis, crude abatacept retention rates, predictors of retention and European League Against Rheumatism (EULAR) response were evaluated in both biologic-naïve and biologic-failure patients. Retention by rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) status was also assessed, in patients with or without baseline radiographic erosions, and by body mass index (BMI).ResultsOverall, 2350/2364 enrolled patients were evaluable (674 biologic naїve; 1676 biologic failure). Baseline characteristics were largely similar in biologic-naïve and biologic-failure groups. Crude retention rates (95% CI) at 12 months were significantly higher in biologic-naїve (78.1%(74.7% to 81.2%)) versus biologic-failure patients (69.9%(67.6% to 72.1%); P<0.001). RF/anti-CCP double positivity predicted higher retention in both patient groups, and remained associated with higher retention in patients with erosive disease. BMI did not impact abatacept retention in either patient group, irrespective of RF/anti-CCP serostatus. Good/moderate EULAR response rate at 12 months was numerically higher in biologic-naїve (83.8%) versus biologic-failure (73.3%) patients. There were no new safety signals.ConclusionHigh levels of intravenous abatacept retention in clinical practice were confirmed, particularly in biologic-naïve patients, including in those with poor RA prognostic factors. Retention was unaffected by BMI, regardless of RF/anti-CCP serostatus.Trial registration numberNCT02109666; retrospectively registered 8 April 2014.
Scalable Private Set Intersection Based on OT Extension
Authors: Pinkas Benny , Schneider Thomas , Zohner Michael 
Published: January 2018

Private set intersection (PSI) allows two parties to compute the intersection of their sets without revealing any information about items that are not in the intersection. It is one of the best studied applications of secure computation and many PSI protocols have been proposed. However, the variety of existing PSI protocols makes it difficult to identify the solution that performs best in a respective scenario, especially since they were not compared in the same setting. In addition, existing PSI protocols are several orders of magnitude slower than an insecure naïve hashing solution, which is used in practice.
In this article, we review the progress made on PSI protocols and give an overview of existing protocols in various security models. We then focus on PSI protocols that are secure against semi-honest adversaries and take advantage of the most recent efficiency improvements in Oblivious Transfer (OT) extension, propose significant optimizations to previous PSI protocols, and suggest a new PSI protocol whose runtime is superior to that of existing protocols. We compare the performance of the protocols, both theoretically and experimentally, by implementing all protocols on the same platform, give recommendations on which protocol to use in a particular setting, and evaluate the progress on PSI protocols by comparing them to the currently employed insecure naïve hashing protocol. We demonstrate the feasibility of our new PSI protocol by processing two sets with a billion elements each.
Letrozole: Delayed Puberty in Males
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data-including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations-precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Multicenter Evaluation of Risk Factors for Aspergillosis in Patients Treated with Lipid Amphotericin B Products: Outcomes, Drug Utilization Parameters, and Benchmarking
Authors: Sutton Shawn Scott , Gomez-Fein Eleanor , Papadopoulos John , Olyaei Ali , Cazes John , Hennenfent Joel , Ambegaonkar Ambarish J. , Lubowski Teresa J. 
Published: January 2018

Purpose To evaluate the use of lipid amphotericin B products in relation to risk factors for aspergillosis and candidemia at the time therapy was initiated. Methods A single-group, concurrent, observational, multicenter study in hospitalized patients receiving a lipid amphotericin B product (Abelcet or AmBisome) was undertaken. The severity of illness, duration of therapy, length of hospital stay, microbiology, all-cause mortality, physician specialty, and clinical characteristics of each patient was recorded. Risk factors for aspergillosis and candidemia and process markers that might identify patients as candidates for lipid amphotericin B therapy were collected. Results One hundred eighty-six patients were enrolled in six US medical centers. One hundred four patients had positive fungal cultures; the majority of positive cultures were for Candida albicans (n = 40) or yeast (n = 27). Sixteen patients had positive cultures for Aspergillus. All patients receiving a lipid amphotericin B product had an overall statistically significantly greater number of risk factors for Candida vs Aspergillus infection. The mean (± SD) number of risk factors for Aspergillus was 2.46 ± 1.97 (range 0–10) and for Candida was 7.77 ± 3.14 (range 1–16) (P < 0.05). Risk factor assessment by medical service showed a statistically significantly larger number of Aspergillus risk factors in the bone marrow transplant (BMT) service compared with all other services (P < 0.05). Conclusions There were fewer documented risk factors for aspergillosis than candidemia in patients receiving a lipid amphotericin B product. Establishing drug usage protocols that include culture analysis, risk factor identification, high-risk medical services, and incorporation of drug use evaluation measures can guide the practitioner in selecting the appropriate therapy for their patients.
Teriparatide
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The May 2003 monograph topics are enfuvirtide, oxybutynin transdermal, gemifloxacin, efalizumab, and hyaluronidase ovine. The DUE is on enfurvirtide.
Gabapentin: Neuropathy (Diabetic)
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Influenza Virus Vaccine, Live, Intranasal
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2003 monograph topics are tositumomab, omalizumab, emtricitabine, testosterone buccal system mucoadhesive, and alfuzosin. The DUE is on omalizumab.
A Review of Clinical Pharmacy Interventions Prior to Implementation of a Personal Digital Assistant Intervention Program in a Community Hospital
Authors: Wilson Amy Friedman , Foral Pamela A. , Nystrom Kelly K. , Heineman Susan M. , Wargo Kurt A. , Wargo Nichole A. 
Published: January 2018

Purpose To evaluate pharmacist interventions and identify areas of improvement prior to decentralization and implementation of a personal digital assistant (PDA) program for documenting interventions. Methods Intervention data were collected from April 1999 to June 2001 using standardized intervention and activity forms. Following collection, data were analyzed to determine the most common medications requiring intervention, acceptance rates, total and estimated cost savings, interventions performed per care unit, and pharmacist time. Results A total of 3030 interventions were captured from April 1999 through June 2001. The most common interventions were dosage or frequency changes (80.6%). The total cost savings for the medication ingredients during the period reviewed was $43,733. The estimated cost savings/cost avoidance of interventions during the study period was $850,417. The most common care units involved in interventions were areas where clinical pharmacy faculty practiced: hematology/oncology, general medicine, and intensive care. From January 2001 to June 2001 a comparison of faculty to clinical pharmacists showed that faculty in three care areas (68 beds) documented 552 interventions, compared with 392 interventions by the clinical pharmacists responsible for the seven other care areas (200 beds) (P< 0.05). Conclusions This review reinforces the benefit of interventions on cost avoidance and patient care. Because a high percentage of interventions was lost due to follow up, implementation of a simplified, uniform approach to clinical intervention reporting through a PDA program and additional decentralization is expected to decrease lost interventions and increase estimated cost avoidance.
Daptomycin
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2004 monograph topics are risperidone long-acting injection; efalizumab; epinastine HCL ophthalmic solution; prussian blue; and bevacizumab. The DUE is on palonosetron.
Rofecoxib: Children, Postoperative Pain Management
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Olanzapine for Injection (Intramuscular)
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2004 monograph topics are lansoprazole injection, trospium chloride, tinidazole, natalizumab, and rubitecan. The DUE is on injectable proton-pump inhibitors.
Pentoxifylline: Aphthous Stomatitis
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Confusion between Various Acetylcysteine Dosage Forms: New Formulation of Cytoxan: Three-Way Name Mix-Up: Error despite Robotics?: Diabetes or Alzheimer Disease?
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers’ names will be published if desired. ISMP may be contacted at the address shown below. The reports described in this column were received through the USP–ISMP Medication Errors Reporting Program (MERP). Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or USP ( www.usp.org ) Web sites or communicated directly to ISMP by calling 1-800-FAIL SAFE or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters’ wishes as to the level of detail included in publications. In 2004, ISMP is celebrating the 10th anniversary of its incorporation as a nonprofit organization. The Institute represents more than 20 years of experience in helping health care practitioners keep patients safe and continues to lead efforts to improve the medication use process.